KARD (Kardigan) OCF Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KARD Kardigan Inc KARD
11 GF Score
Price $20.42
! 1 Warning Sign
View Full Analysis

What is Kardigan OCF Margin %?

Kardigan KARD +2.77% 11 OCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates KARD with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 953 Biotechnology companies, Kardigan ranks worse than 104931.69% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Kardigan's Cash Flow from Operations for the six months ended in Dec. 2025 was $-151.06 Mil. Kardigan's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Kardigan's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Kardigan's current OCF Yield % is -8.28%.

The historical rank and industry rank for Kardigan's OCF Margin % or its related term are showing as below:


KARD's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -64.23
* Ranked among companies with meaningful OCF Margin % only.

Kardigan OCF Margin % Related Terms

Kardigan OCF Margin % Historical Data

* Premium members only.

The historical data trend for Kardigan's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kardigan OCF Margin % Chart

Kardigan Annual Data
Trend Dec24 Dec25
OCF Margin %
0.00 0.00

Kardigan Semi-Annual Data
Dec24 Dec25
OCF Margin % 0.00 0.00
KARD
11GF Score
Kardigan Inc KARD
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kardigan OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Kardigan's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-151.056/0
= %

Kardigan's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-151.056/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Kardigan (KARD) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kardigan and its competitors. According to the industry distribution chart, Kardigan ranks #999999 out of 953 companies in the Biotechnology industry.
Is Kardigan's OCF Margin % too high?
Kardigan's current OCF Margin % is 0.00%. Based on the distribution chart, Kardigan ranks #999999 out of 953 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kardigan has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kardigan's OCF Margin % compare to OCUL and GHRS?
According to the Biotechnology industry distribution chart, Kardigan ranks #999999 out of 953 companies for OCF Margin %. This places Kardigan in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kardigan and its competitors. Kardigan's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kardigan stock overvalued right now?
Kardigan (KARD) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Kardigan's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Kardigan (KARD), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kardigan Business Description

Address 506 Carnegie Center Drive, Suite 201, Princeton, NJ, USA, 08540
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
11GF Score

Get the complete analysis for KARD

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.42
Price